Drug intelligence / Profile preview

OMA-102

Development stage: Unknown
Lead developer: EMS
Modality: Small Molecules
Administration: Oral

Overview

OMA-102 is an oral small molecule drug under development by EMS SA (Brazil) for the treatment of female pattern hair loss (female pattern baldness). It is being evaluated primarily for its ability to promote hair growth in the mid-frontal area of the scalp. The drug has reached Phase 3 clinical trials, with a multicenter, randomized, double-blind study underway to assess its efficacy and safety compared to placebo in women with female pattern hair loss. The precise mechanism of action has not been disclosed publicly. Its primary therapeutic area is skin and musculoskeletal diseases[1][2][5].

Beyond the preview

Go deeper on OMA-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OMA-102.

Explore the full profile